Delirium occurs in up to 30% of hospitalised patients and is associated with prolonged hospital stay and increased morbidity and mortality. Recently published reports have suggested that the standard drug for delirium, haloperidol, a typical antipsychotic that may cause adverse extrapyramidal symptoms among patients, may be replaced by atypical antipsychotics such as risperidone, olanzapine or quetiapine, that are as effective as haloperidol in controlling delirium, but that have a lower incidence of extrapyramidal adverse effects.
To compare the efficacy and incidence of adverse effects of haloperidol with risperidone, olanzapine, and quetiapine in the treatment of delirium.
The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 7 August 2006 using the search terms: haloperidol or haldol or risperidone or risperdal* or quetiapine or seroquel* or olanzapine or zyprexa* or aminotriazole or sertindole or leponex* or zeldox* or ziprasidone.
Types of studies included unconfounded, randomised trials with concealed allocation of subjects. For inclusion trials had to have assessed patients pre- and post-treatment. Where cross-over studies are included, only data from the first part of the study were examined. Interrupted time series were excluded. Length of trial and number of measurements did not influence the selection of trials for study. Where indicated, individual patient data were requested for further examination.
Data collection and analysis
Two reviewers extracted data from included trials. Data were pooled where possible, and analysed using appropriate statistical methods. Odds ratios of average differences were calculated. Only 'intention to treat' data were included. Analysis included haloperidol treated patients, compared with placebo.
Three studies were found that satisfied selection criteria. These studies compared haloperidol with risperidone, olanzapine, and placebo in the management of delirium and in the incidence of adverse drug reactions. Decrease in delirium scores were not significantly different comparing the effect of low dose haloperidol (< 3.0 mg per day) with the atypical antipsychotics olanzapine and risperidone (Odds ratio 0.63 (95% CI 10.29 to 1.38; P = 0.25). Low dose haloperidol did not have a higher incidence of adverse effects than the atypical antipsychotics. High dose haloperidol (> 4.5 mg per day) in one study was associated with an increased incidence of extrapyramidal adverse effects, compared with olanzapine. Low dose haloperidol decreased the severity and duration of delirium in post-operative patients, although not the incidence of delirium, compared to placebo controls in one study. There were no controlled trials comparing quetiapine with haloperidol.
There is no evidence that haloperidol in low dosage has different efficacy in comparison with the atypical antipsychotics olanzapine and risperidone in the management of delirium or has a greater frequency of adverse drug effects than these drugs. High dose haloperidol was associated with a greater incidence of side effects, mainly parkinsonism, than the atypical antipsychotics. Low dose haloperidol may be effective in decreasing the degree and duration of delirium in post-operative patients, compared with placebo.
These conclusions must be tempered by the observation that they are based on small studies of limited scope, and therefore will require further corroborating evidence before they can be translated into specific recommendation for the treatment of delirium.
約30%的住院病人會出現瞻妄的情況，這會延長住院天數以及增加罹病率及死亡率。最近有一些報導顯示治療瞻妄的標準藥物如haloperidol，容易有錐體外症狀的副作用，而這些可由一些非典型抗精神病藥物，像risperidone, olanzapine, quetiapine來取代，它們對於控制瞻妄的效果與haloperidol 一樣有效，但錐體外症狀的副作用發生率卻較低
在2006年8月7日，從Specialized Register of the Cochrane Dementia and Cognitive Improvement Group資料庫中搜尋下列名詞:haloperidol或haldol或risperidone或risperdal或quetiapine或seroquel或olanzapine或zyprexa 或aminotriazolesertindole或leponex或zeldox或ziprasidone
3個研究是符合我們選取的要件。這些研究比較haloperidol rieperidone, olanzapine 以及安慰劑在治療瞻妄以及發生藥物副作用的情況。瞻妄指數的減少在使用低劑量的haloperidone(< 3.0 mg 每天)與非典型的抗精神病藥物(olanzapine 及 risperiodone)沒有明顯差異。(OR = 0.63)(95% CI 10.29 to 1.38; P = 0.25)。 低劑量的haloperidol 比起非典型的抗精神病藥物並不會有較高的副作用發生率。在其中一個研究中，高劑量的haloperidol (> 4.5 mg 每天)比起olanzapine會有較高錐體外徑路副作用發生的機會。在某一個研究中顯示，比起安慰劑,低劑量的haloperidol可以減輕術後病人瞻妄的嚴重度及時間,而非瞻妄的發生率。並沒有具控制組的試驗來比較quetiapine 及 haloperidol
此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌
有一些來自隨機對照試驗(RCTs)的證據顯示抗精神病藥物在不同劑量治療不同瞻妄的表現確實是有效的。Haloperidol (<3.5 mg/d)，risperidone及olanzapine有較少的副作用，但在治療瞻妄者一樣的有效。高劑量的haloperidol(>4.5 mg/d)與olanzapine相比，則常出現帕金森氏症的副作用。術前投與haloperidol可減輕術後瞻妄的期間與嚴重度。所有的研究規模都太小而需要重複進行